Investors often rely on the healthcare sector to safeguard their investments. This is because the demand for healthcare services does not vary too much with respect to market conditions, and thus, the sector offers sufficient protection to the capital invested. Many pharmaceutical companies also offer regular dividends. Companies that consistently pay out dividends are financially stable and generate steady cash flows, irrespective of market conditions. Mutual funds are the perfect choice for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.
Below, we share with you three top-ranked Healthcare mutual funds, namely BlackRock Health Sciences Opportunities Portfolio Investor Shares SHSAX, Janus Henderson Global Life Sciences JNGLX and Fidelity Advisor Biotechnology Fund FBTIX. Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy) and is expected to outperform its peers in the future. Investors can click here to see the complete list of funds.
BlackRock Health Sciences Opportunities Portfolio Investor Shares primarily invests in equity securities of health sciences companies, including healthcare equipment, providers, biotechnology and pharmaceuticals, while also investing in related international companies.
BlackRock Health Sciences Opportunities Portfolio Investor Shares has three-year annualized returns of 5.5%. As of February 2026, SHSAX held 153 issues, with 11.4% of its assets invested in Eli Lilly.
Janus Henderson Global Life Sciences invests primarily in securities of companies with a life science focus, including significant exposure to businesses within the broader life sciences sector.
Janus Henderson Global Life Sciences has three-year annualized returns of 9.9%. JNGLX has an expense ratio of 0.81%.
Fidelity Advisor Biotechnology Fund focuses on biotech-related stocks worldwide, targeting firms driving scientific and technological advances, using fundamental analysis to assess financial strength, industry position and broader market conditions, while maintaining a non-diversified portfolio.
Fidelity Advisor Biotechnology Fund has three-year annualized returns of 20.3%. Eirene Kontopoulos has been the fund manager of FBTIX since July 2018.
To view the Zacks Rank and the past performance of all Healthcare mutual funds, investors can click here to see the complete list of healthcare mutual funds.
Want key mutual fund info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>View All Zacks #1 Ranked Mutual Funds
Get Your Free (FBTIX): Fund Analysis Report
Get Your Free (JNGLX): Fund Analysis Report
Get Your Free (SHSAX): Fund Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
